IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: Ritzeler, et al.

Art Unit: 1624

Application No.: 10/642,970

Filed: August 18, 2003

Title: Indole Derivatives or Benzimidazole
Derivatives for Modulating IkB Kinase

UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 CFR. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 CFR. 1.56(b), the filling of this Information Disclosure Statement is not intended to, pursuant to 37 CFR. 1.97(b), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 CFR. 1.97(b), the filling of this information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §197(b) because it accompanies the new patent application submitted berewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(o) or credit any overnawment to Account No. 18-1982.

(b)	This	s Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
	1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
	or a	notice of allowance under §1.311, whichever occurs first.
	(1)	The undersigned attorney certifies that each item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application not more than three months prior
		to the filing of this statement;
	(2)	The undersigned attorney certifies that no item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application or, to the knowledge of the
		undersigned attorney after making reasonable inquiry, was known to any
		individual designated in §1.56(c) more than three months prior to the filing of this
		statement; or
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) i
		authorized.

Respectfully submitted.

/Julie Anne Knight/ Julie Anne Knight, Reg. No. 48,867 Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2002/0063 US NP

lease type a plus sign (+) inside this box -> 🗸	PTO/SB/08A (10-9
Ψ.	Approved for use through 10/31/99, OMB 0661-003
	Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Inder the Paperwork Reduction Act of 1995, no persons are required to result	and to a collection of information unless it contains a valid OMB control number

to Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid DMB control number.									
Substit	ite for form 1449A/PTC			Complete if Known					
				Application Number	10/642970				
			SCLOSURE	Filing Date	08-18-2003				
STA	TEMENT B	Y	APPLICANT	First Named Inventor	RITZELER				
				Group Art Unit	1624				
	(use as many shee	als a	s necessary)	Examiner Name	RAO, Deepak R.				
Sheet	1	of	1	Attorney Docket Number	DEAV2002/0063 - US - NP				

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.1	U.S. Pater Number	Kind Code ² (d'Anount)	Name of Palentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Peesages or Relevant Figures Appear
	-		-1-1			
_						
_		_	-		+	
-	_		-			
-				•	_	
_	_				 	
			-			
\neg			\neg			
			\neg			
			$-\Box$			
			-			
			\rightarrow			
_	_		-			
-			\rightarrow			
-	-		-			
	-					
	-					

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	ner Cite Foreign Patent Document		Name of Patentoe or Applicant of Cited Document	Date of Publication of Gled Document MM-DD-YYYY	Peges, Columne, Lines, Where Relevant Pesseges or Relevant Process Appear	Ţ6			
	-	WQ	94/08962	\rightarrow		HARTMAN, George, et al.	04-28-1994		П
\vdash	\vdash			\rightarrow	-		 		Н
	=	_		\dashv	_		 		Н
		\vdash		=	=		-		
-	-	-		\rightarrow	-		 		Н
									口
	_	-		\rightarrow	_		-		Н

Examiner Signature		Date Considered					

*Unique Alption designation number: *See state-bed fields of U.S. Palest Coocuments. *Edited Office that issued the document, by the love-bind one (WPO State-des 513... *End signates parted documents, by an incident of the specified here) are fine region of the improvement process the season inventor of the popular document. *Plack of documents by the appropriate publics is indicated on the document under WPO Statedord ST, 16 of possible. *Applicate in a place or exchain with their English frequency Transitions in a basicale.



^{*}EXAMINER: Initial if reference considered, whether or not clostion is in conformance with MPEP 609. Draw line through obtain if not in conformance and not considered, Induse copy of this form with next communication to applicant.